Charles River Laboratories (CRL) Financial Analysis & Valuation | Quarter Chart
Charles River Laboratories (CRL)
CRLPrice: $216.11
Fair Value: 🔒
🔒score
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Mode... more
Charles River Laboratories International, Inc., a non-clinical contract research organization, provi... more
Description
Shares
| Market Cap | $10.64B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | James C. Foster |
| IPO Date | 2000-06-23 | CAGR | 0.12% |
| Employees | 18,700 | Website | www.criver.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.05% | Total Yield | 0.05% |
CRL chart loading...
Fundamentals
Technicals
| Enterprise Value | $12.38B | P/E Ratio | -140.33 |
| Forward P/E | 14.48 | PEG Ratio | — |
| P/S Ratio | 186.73 | P/B Ratio | 221.95 |
| P/CF Ratio | 946.17 | P/FCF Ratio | 1288.78 |
| EPS | $-1.54 | EPS Growth 1Y | -119.52% |
| EPS Growth 3Y | -118.37% | EPS Growth 5Y | -126% |
| Revenue Growth 1Y | -0.92% | Gross Margin | 0.32% |
| Operating Margin | 0.03% | Profit Margin | -0.02% |
| ROE | -0.02% | ROA | -0.01% |
| ROCE | 0.02% | Current Ratio | 1.36 |
| Quick Ratio | 1.1 | Cash Ratio | 0.17 |
| Debt/Equity | 0.83 | Interest Coverage | 1.07 |
| Altman Z Score | 2.61 | Piotroski Score | 6 |